Pharmacotherapy in Type 1 Diabetes

McGibbon, Angela; Richardson, Cindy; Hernandez, Cheri Ann; Dornan, John

doi:10.1016/j.jcjd.2013.01.020

Cited by 17 publications

(9 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with type 1 diabetes mellitus (T1DM) require lifelong insulin therapy, and in order to maintain normoglycaemia, escalating doses of insulin are often necessary as the severity of the disease progresses . Insulin is associated with weight gain, however, which poses significant cardiovascular risks and challenges with regard to treatment adherence .…”

Section: Introductionmentioning

confidence: 99%

Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus

Tang

Leil

Johnsson

et al. 2016

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus

Tang

Leil

Johnsson

et al. 2016

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…SMBG allows for the detection of hyperglycemia and hypoglycemia to inform disease management [ 2 , 3 ]. Compared with insulin, the risk of hypoglycemia associated with non-insulin therapies is lower and is generally limited to secretagogues [ 2 , 3 , 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Differences in self-monitored, blood glucose test strip utilization by therapy for type 2 diabetes mellitus

Tavares

Duclos²,

Brabant³

et al. 2016

Acta Diabetol

View full text Add to dashboard Cite

AimsTo determine whether blood glucose test strip (BGTS) utilization in patients with type 2 diabetes (T2D) is associated with the type of diabetes therapy, classified according to hypoglycemic risk.MethodsA retrospective, longitudinal (2006–2012) study of Canadian private drug plans (PDP) and Ontario Public Drug Programs (OPDP) prescription claims was conducted. Analyses were restricted to patients with T2D with or without a claim for BGTS. Daily BGTS utilization (TS/patient/day) was evaluated by diabetes therapy classified by hypoglycemic risk. Multivariate analyses were conducted to identify determinants of BGTS utilization.ResultsThe T2D cohort comprised 5,759,591 observations from 1,949,129 claimants. Mean BGTS utilization was 0.84 TS/patient/day and differed between PDP and OPDP (0.66 vs. 1.00). Daily utilization was greatest in patients receiving therapy associated with a pre-defined high risk of hypoglycemia [insulin: basal + bolus (2.16), premixed (1.65), basal (1.16), other insulin regimens (2.13), and sulfonylureas (0.74)] versus non-sulfonylurea non-insulin-based regimens (0.52). For non-insulin therapy, BGTS utilization was greater for patients on multiple non-insulin therapies versus monotherapy (0.74 vs. 0.53 TS/patient/day). In multivariate analyses, drivers for BGTS utilization included insulin use, previous BGTS use, and female gender. Previous diabetes therapy and duration of therapy were negatively correlated with BGTS utilization.ConclusionsBGTS utilization varies depending on the type of therapy used to treat T2D according to hypoglycemic risk. Decision making regarding BGTS needs to account for robust analyses of current utilization and its value in those settings, including in patients not receiving diabetes therapy and the prevalence of circumstances conducive to more intensive monitoring.

show abstract

“…Pharmacists who have active diabetes practices lead these sessions and the content is consistent with current guideline recommendations and training material provided to patients who are starting insulin. 3,14,15 The session runs for 50 minutes with a ratio of 8 students to 1 pharmacist in each session. Students are encouraged to attempt at least one blood glucose check and mock insulin injection while they are directly supervised by the pharmacists.…”

Section: Methodsmentioning

confidence: 99%

Effect of an Experiential Exercise in Diabetes Management on Pharmacy Students’ Fear and Perceived Pain of Injection and Fingertip Lancing

Sahnan

Simpson

2015

American Journal of Pharmaceutical Education

View full text Add to dashboard Cite

Objective. To determine if a diabetes management exercise would change pharmacy students' fear and perceived pain associated with injection and fingertip lancing. Methods. Before and after a 1-week experiential exercise of living with diabetes, students completed questionnaires measuring fear of injection and self-testing and recorded the level of perceived pain associated with injection and fingertip lancing. Anticipated (baseline) and experienced (follow-up) scores were compared. Results. Forty students returned both baseline and follow-up survey instruments. Reported levels of fear decreased significantly for self-injection ( p,0.0001) and self-testing ( p50.0089) after the exercise. Experienced pain was also significantly lower than anticipated pain for both injection ( p,0.0001) and fingertip lancing ( p50.013). Experienced pain of injection was significantly lower than fingertip lancing ( p50.017). Conclusion. Participation in the exercise significantly reduced pharmacy students' fear and perceived pain associated with injection and fingertip lancing. Students can use information gained from their experiences when helping patients manage diabetes.

show abstract

Pharmacotherapy in Type 1 Diabetes

Cited by 17 publications

References 84 publications

Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus

Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus

Differences in self-monitored, blood glucose test strip utilization by therapy for type 2 diabetes mellitus

Effect of an Experiential Exercise in Diabetes Management on Pharmacy Students’ Fear and Perceived Pain of Injection and Fingertip Lancing

Contact Info

Product

Resources

About